Why the study?
Does ticagrelor monotherapy compared to ticagrelor and aspirin alter platelet activation pathways in patients after percutaneous coronary intervention?
Does ticagrelor monotherapy compared to ticagrelor and aspirin alter platelet activation pathways in patients after percutaneous coronary intervention?
Ticagrelor monotherapy provides similar inhibition of most platelet activation pathways as dual therapy with aspirin, but leaves glycoprotein VI-mediated activation incompletely inhibited, which may explain lower bleeding rates seen in clinical trials.
Answers are grounded in this paper and cite their sources.
May support ticagrelor monotherapy post-PCI to reduce bleeding; extends mechanistic basis for differential pathway effects.
receptor agonist and surface activation marker binding with 5 μmol/L TRAP-6 or 0.5 μg/mL collagen related peptide were the same between the treatment groups. Conclusions Patients with PCI show similar levels of inhibition of most platelet activation pathways with TIC compared with dual therapy with TIC + ASP. However, the greater aggregation response with collagen related peptide during TIC indicates incomplete inhibition of glycoprotein VI (collagen) receptor-mediated platelet activation. This difference in pharmacodynamic response to anti-platelet medication may contribute to the lower bleeding rates observed with TIC compared with dual antiplatelet therapy in recent clinical trials. Registration Information URL: https://www.isrctn.com; Unique Identifier ISRCTN84335288.
No takes yet. Share an insight, caveat, or question.
Johnson et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: